Amylyx Pharmaceuticals, Inc. (AMLX) Form 8-K — Aug 6, 2026
Amylyx Pharmaceuticals reported a net loss of $43.4 million for the second quarter of 2026, with research and development expenses decreasing to $23.8 million from $27.2 million in the prior year period. The company ended the quarter with $250.8 million in cash, cash equivalents, and short-term investments, and expects its current operating plans to fund operations into 2028.
Key figures
- Net Loss
- 43.4
- Rd Expenses
- 23.8
- Sga Expenses
- 21.9
- Cash Position
- 250.8
- Rd Expenses Yoy
- -12.5
- Sga Expenses Yoy
- 40.1
- Net Loss Per Share
- 0.39
- Shares Outstanding
- 111.2
Price after filing
1 day: -0.1%7 days: +2.8%30 days: +55.9%
Close on the filing date to close N calendar days later (from $21.87). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.